Literature DB >> 6276051

Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism.

E F Adams, M J Ashby, S M Brown, M C White, K Mashiter.   

Abstract

Bromocriptine (0.13-13 microM) significantly inhibited ACTH secretion in a dose-dependent manner when added to cell cultures of a human corticotrophic adenoma for 24 h. Haloperidol (13 microM), but not serotonin (13 microM), blocked this inhibition but had no significant effect when added alone. In addition, dopamine (10 microM) reduced ACTH secretion during a 4-h incubation, whereas serotonin (0.01-10 microM) was ineffective. An ectopic ACTH secreting lung carcinoid was non-responsive to doses of bromocriptine up to 13 microM. These results demonstrate a direct suppressive action of bromocriptine on a human pituitary corticotrophic adenoma through dopaminergic rather than serotoninergic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6276051     DOI: 10.1111/j.1365-2265.1981.tb00691.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Dopamine D2 receptor gene expression in human adenohypophysial adenomas.

Authors:  L Stefaneanu; K Kovacs; E Horvath; M Buchfelder; R Fahlbusch; L Lancranjan
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 2.  Pituitary-directed medical therapy in Cushing's disease.

Authors:  Stephan Petersenn; Maria Fleseriu
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 4.  Managing Cushing's disease: the state of the art.

Authors:  Annamaria Colao; Marco Boscaro; Diego Ferone; Felipe F Casanueva
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

5.  Effect of short and long-term administration of lisuride in Cushing's disease.

Authors:  M Boscaro; G Merola; E Serafini; F Mantero
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

6.  Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

Authors:  Teresa Gagliano; Carlo Filieri; Mariella Minoia; Mattia Buratto; Federico Tagliati; Maria Rosaria Ambrosio; Marcello Lapparelli; Matteo Zoli; Giorgio Frank; Ettore degli Uberti; Maria Chiara Zatelli
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

7.  Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.

Authors:  Beverly Mk Biller; Annamaria Colao; Stephan Petersenn; Vivien S Bonert; Marco Boscaro
Journal:  BMC Endocr Disord       Date:  2010-05-17       Impact factor: 2.763

8.  Surgical management of the ectopic ACTH syndrome.

Authors:  C J Davies; G F Joplin; R B Welbourn
Journal:  Ann Surg       Date:  1982-09       Impact factor: 12.969

9.  Cushing's disease: clinical and laboratory response to bromocriptine therapy.

Authors:  M O de Pinho; R C Antunes; M B Lima; C C Francalanci; S Franco
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256

10.  Alpha-1 adrenergic blockade: a possible mechanism of action of dopaminergic drugs on ACTH secretion.

Authors:  M Boscaro; A M Menegus; F Mantero
Journal:  J Endocrinol Invest       Date:  1985-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.